Abivax receives $920 million in cash to prepare for US launch: CEO
AbivaxThe latest round of funding allows the biotech to move toward launching its intestinal disease drug in the United States…
pharmaceutical products
AstraZeneca shares fall 9% after heart drug trial falls short of target
Actions of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to…
Chan Zuckerberg Biohub to open new round of funding for rare diseases
Biohub, a nonprofit research organization funded by the Chan Zuckerberg Initiative, announced Thursday that it will open another round of…
US opens tariff investigation targeting Germany's drug pricing policies
The United States has launched an investigation into Germany's pharmaceutical policies over what it called “persistent underpayment” for drugs, as…
Biotech IPO window is open, but big pharma M&As set the pace: bankers
Public markets are beginning to reopen for biotech companies after several years of subdued activity. But stronger companies are still…
Trump's FDA Commissioner Marty Makary Outside
Food and Drug Administration Commissioner Marty Makary speaks during an announcement at the Department of Health and Human Services on…
Intellia's Crispr Gene Editing Treatment Succeeds in Phase 3 Trial
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, United States. Spencer Scholarship | Universal Image Group | fake images…
The reality of Trump's drug prices will be set in the next 18 months
NovartisThe CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and that…
Regeneron signs drug pricing deal with Trump, will offer free hearing loss therapy
Regeneron He agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump,…
Regeneron weighs overseas pricing of gene therapy for rare hearing loss
Regeneron Pharmaceuticals will make its recently approved gene therapy for a rare genetic form of hearing loss available for free…